Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the Spanish registry

• Published in: Pediatric rheumatology online journal Vol. 22; no. 1; pp. 66 - 8
• Main Authors: Carriquí-Arenas, Sonia, Mosquera, Juan Manuel, Quesada-Masachs, Estefanía, López, Mireia, Clemente, Daniel, Boteanu, Alina, Udaondo, Clara, de Inocencio, Jaime, Nieto, Juan Carlos, Riancho, Leyre, Núñez, Esmeralda, Sánchez-Manubens, Judith, Lirola, María José, Roldán, Rosa, Camacho, Marisol, Martínez, Melania, Medrano, Marta, Alcañiz, Paula, Antón, Jordi, Iglesias, Estíbaliz
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.07.2024; BioMed Central; BMC
• Subjects: Autoantibodies - blood; Child; Child, Preschool; Children; Clinical features; Deglutition Disorders - epidemiology; Deglutition Disorders - etiology; Dermatomyositis; Dermatomyositis - diagnosis; Dermatomyositis - epidemiology; Diagnosis; Diseases; Epidemiology; Female; Humans; Juvenile dermatomyositis; Male; Medical tests; Muscle Weakness - epidemiology; Muscle Weakness - etiology; Prognosis; Prognostic factors; Registries; Retrospective Studies; Spain - epidemiology; Spain; Juvenile dermatomyositis; Medical tests; Clinical features; Prognostic factors
• ISSN: 1546-0096; 1546-0096
• DOI: 10.1186/s12969-024-00999-9

Juvenile Dermatomyositis (JDM) is the most common chronic idiopathic inflammatory myopathy in children. The diagnosis is clinical. Baseline laboratory and complementary studies trace the phenotype of these patients. The objective of this study was to describe epidemiological, clinical and laboratory characteristics at diagnosis of JDM patients included in the Spanish JDM registry, as well as to identify prognostic factors on these patients. We retrospectively reviewed clinical features, laboratory tests, and complementary studies at diagnosis of JDM patients included on the Spanish JDM registry. These data were analyzed to assess whether there was a relationship with the development of complications and time to disease inactivity. One hundred and sixteen patients from 17 Spanish paediatric rheumatology centres were included, 76 girls (65%). Median age at diagnosis was 7.3 years (Interquartile range (IQR) 4.5-10.2). All patients had pathognomonic skin lesions at the beginning of the disease. Muscle weakness was present in 86.2%. Median Childhood Muscle Assessment Scale was 34 (IQR 22-47). Twelve patients (34%) had dysphagia and 3,5% dysphonia. Anti-p155 was the most frequently detected myositis specific antibody, followed by anti-MDA5. Twenty-nine patients developed calcinosis and 4 presented with macrophage activation syndrome. 70% reached inactivity in a median time of 8.9 months (IQR 4.5-34.8). 41% relapsed after a median time of 14.4 months (IQR 8.6-22.8) of inactivity. Shorter time to treatment was associated with better prognosis (Hazard ratio (HR) = 0.95 per month of evolution, p = 0.02). Heliotrope rash at diagnosis correlates with higher risk of development complications. We describe heliotrope rash as a risk factor for developing complications in our cohort of JDM patients, an easy-to-evaluate clinical sign that could help us to identify the group of patients we should monitor closely for this complication.